MedTech Acquisition Corp - Ordinary Shares - Class A

NASDAQ:MTAC   3:29:04 PM EDT
10.13
+0.06 (+0.60%)
Debt Financing / Related, Mergers / Acquisitions

Trisalus Life Sciences To Become Publicly Traded Through Merger

Published: 11/14/2022 13:23 GMT
MedTech Acquisition Corp - Ordinary Shares - Class A (MTAC) - Trisalus Life Sciences to Become Publicly Traded Through Merger With Medtech Acquisition Corporation.
Medtech Acquisition Corp - Expected Cash at Closing Includes Up to $50 Million From an Anticipated Convertible Note From Leading Institutional Investor.
Medtech Acquisition Corp - Transaction Represents a Post-transaction Market Capitalization of Approximately $244.4 Million for Trisalus Upon Closing.
Medtech Acquisition - Combined Co Will Be a Publicly Traded Comp, Common Stock is Expected to Be Listed on Nasdaq Stock Exchange Under Ticker "tlsi".
Medtech Acquisition Corp - at Completion of Transaction, Company Expects to Have at Least $60 Million in Cash, Assuming Significant Redemptions.
Medtech Acquisition Corp - Longer Term, Trinav is Expected to Support Growth and Effectiveness of Sd-101.